136 related articles for article (PubMed ID: 144332)
1. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
Summaria L; Boreisha IG; Arzadon L; Robbins KC
Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
[No Abstract] [Full Text] [Related]
2. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
[TBL] [Abstract][Full Text] [Related]
3. Alpha 2-plasmin inhibitor deficiency.
Lipinski B; Gurewich V
Lancet; 1979 Feb; 1(8111):329. PubMed ID: 84984
[No Abstract] [Full Text] [Related]
4. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
5. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
6. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.
Gurewich V; Hyde E; Lipinski B
Blood; 1975 Oct; 46(4):555-65. PubMed ID: 126095
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
Brosstad F
Thromb Res; 1979; 15(3-4):497-504. PubMed ID: 158847
[No Abstract] [Full Text] [Related]
8. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
9. A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin.
Moroz LA; Gilmore NJ
Blood; 1975 Oct; 46(4):543-53. PubMed ID: 126094
[TBL] [Abstract][Full Text] [Related]
10. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
11. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
Lijnen HR; Van Hoef B; De Cock F; Collen D
Blood; 1989 May; 73(7):1864-72. PubMed ID: 2713507
[TBL] [Abstract][Full Text] [Related]
12. The conversion of streptokinase-plasminogen complex to SK-plasmin complex in the presence of fibrin or fibrinogen.
Takada Y; Takada A
Thromb Res; 1989 Apr; 54(2):133-9. PubMed ID: 2526391
[TBL] [Abstract][Full Text] [Related]
13. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
14. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
Bookstein JJ; Saldinger E
Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363
[TBL] [Abstract][Full Text] [Related]
15. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
Sakai M; Watanuki M; Matsuo O
Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
[TBL] [Abstract][Full Text] [Related]
17. The search for the ideal thrombolytic agent.
Verstraete M
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
[TBL] [Abstract][Full Text] [Related]
18. Comparison of affinities of urokinase and tissue plasminogen activator for fibrin clots.
Homandberg GA; Wai T
Thromb Res; 1989 Aug; 55(4):493-501. PubMed ID: 2510355
[TBL] [Abstract][Full Text] [Related]
19. Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
Zhalyalov AS; Panteleev MA; Gracheva MA; Ataullakhanov FI; Shibeko AM
PLoS One; 2017; 12(7):e0180668. PubMed ID: 28686711
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of fibrinolytic enzymes in vivo.
Ambrus JL; Weber FJ; Ambrus CM
J Med; 1979; 10(1-2):99-119. PubMed ID: 158624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
